0% found this document useful (0 votes)
9 views18 pages

Managing Digitalis Toxicity in Patients

The document discusses the management of digitalis toxicity, focusing on digoxin, a cardiac glycoside used for controlling ventricular rates in atrial fibrillation and heart failure. It outlines the drug's mechanism of action, pharmacological effects, dosage, precautions, interactions, toxicity symptoms, and management strategies. Additionally, it highlights the use of digoxin-specific antibodies like Digibind for reversing cardiotoxicity.
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
9 views18 pages

Managing Digitalis Toxicity in Patients

The document discusses the management of digitalis toxicity, focusing on digoxin, a cardiac glycoside used for controlling ventricular rates in atrial fibrillation and heart failure. It outlines the drug's mechanism of action, pharmacological effects, dosage, precautions, interactions, toxicity symptoms, and management strategies. Additionally, it highlights the use of digoxin-specific antibodies like Digibind for reversing cardiotoxicity.
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

MANAGEMENT OF

DIGITALIS TOXICITY
PRESENTED BY

SHAILJA VERMA
MBBS student
BATCH-22
ROLL NO. 64
DIGITALIS
Drug class-cardiac glycosides
obtained from plants

Digitalis lanata-Digoxin

Digitalis purpurea-digitoxin

toad skin-bufotoxin

strophanthus gratus-ouabain
USES
(DIGOXIN ONLY GLYCOSIDE THAT IS CURRENTLY IN USE)

 Controlling ventricular rate in

• atrialflutter(AFI)

• atrial fibrillation (AF)


 Congestive Heart failure

 In paroxysmal supraventricular
tachycardia(PSVT)
Mechanism
of action Increase
iontropism
Inhibit Na+/K+
pump In
myocardium

Caption
It blocks the Na+/k+ pump of cardiac muscle

Increase the intracellular sodium

Increase the intracellular calcium

Results in forceful contraction of


myocardium

Greater output per beat


Complete emptying of
heart

Delayed circulation
improved

.
PHARMACOLOGICAL
EFFECTS
On heart - Force of contraction increase
Heart rate is decreased

n kidney- causes diuresis in CHF patients

On CNS - In therapeutic dose little apparent effect. Higher


doses causes clinical manifestations

 Digoxin once a pivotal for heart failure, it is no longer


a first line drug .the two main limitations are low
margin of safety and lack of effect on neurohumoral
contributors to pathogenesis of heart failure.
DOSAGE

• Therapeutic level- 0.5-2nd/ml


• Therapy initiated within
maintenance
dose(0.125-0.25mg/day) without
any loading dose

• For an early response loading dose of 0.75 -1.25 mg


spread over 24-48 hrs may be given in the
beginning,but requires close monitoring
Pharmacokinetics
of digoxin
PRECAUTIONS AND
CONTRAINDICATIONS

 Hypokalemia : digitalis toxicity enhances


 Elderly,renal or severe hepatic disease :patients are more
susceptible to digoxin toxicity
 Thyrotoxicosis: paients are more prone to develop arryhthmias
 Hypothyroidism : digoxin removal is slowed down
 Ventricular tachycardia : digitalis may leads to fibrillation
 Partial AV block : may lead to complete AV block
 Wolff-Parkinson-white syndrome : digoxin is contraindicated ,VF
may occur
 Digoxin can increase the chances of reentry by slowing conduction in
the normal AV bundle and accelerating it in aberrant path
INTERACTIONS
1. DIURETICS: cause hypokalemia which increases the risk of digitalis
arrythmias;potassium supplements should be given prophylactically.
2. Calcium : syngerises with digitalis – causes toxicity.
3. Quinidine : reduces binding of digoxin to tissue proteins as well as its
renal and biliary clearance by inhibiting efflux transporter P-
glycoprotein – plasma concentration doubles – toxicity can occur.
4. Adrenergic drugs : can induce arrythmias;increase ectopic
automaticity.
5. Digoxin absorption may be reduced by
metoclopramide,neomycin,antacids.
6. Absorption increase by atropinic drugs including tricyclic
antidepressants
7. Propranolol,verapamil, may additively depress AV conduction and
oppose inotropic effect
TOXICITY AND ADVERSE
EFFECT
 Digoxin is a cumulative drug with low margin of safety (therapeutic
index- 1.5- 3).
 ABOUT 25%patients develop one or more toxic symptoms.
• Extracardiac - anorexia ,nausea,vomiting .first reported due gastric
irritation,CTZ stimulation.
• diarrhoea can occur , fatigue, malaise,headache, mental
confusion ,disorientation, hyperapnoea, skin rash.
• Cardiac – arrhythmias , pulsus bigeminus , nodal and ventricular
extrasystoles ,ventricular tachycardia ,ventricular fibrillation
• Sometimes complete AV block
• Severe bradycardia
In 2/3 of patients extracardiac symptoms precede cardiac
toxicity
1
3
MANAGMENT

 Discontinuation of digoxin : stop at the earliest sign of toxicity


 Monitor vital sign : regularly monitor the patients vitals.
 Electrolyte montoring : particulary potassium
 Supportive care : provide supportive care to manage symptoms
such as nausea,vomiting and arryhthmias,in serious cases
pacemaker may be required.
 Prevention : educate patients on the proper use of digoxin
medications,including dosage,sign of toxicity and when gto seek
medical help.
TREATMENT
 For tachyarryhthmias – infuse KCL [Link]/hour
 (max [Link]) i.v or orally give in milder cases
 K+ is contraindicated in higher degree of av block is present , because can lead
to complete av block and ventricular asystole may be precipitated
 For ventricular arrhythmias – lidocaine i.v is the DOC it suppresses the
automaticity
 For supraventricular arrhythmias propranolol may be given i.v or orally
depending on the urgency
 For AV block and bradycardia – the T/t of choice is cardiac pacing through a
temporarily inserted pacemaker. Atropine 0.6-1.2mg i.m may help
Cont..

DIGIBIND
DIGOXIN ANTIBODY – Digoxin specific antibody is highly effective in
reversing cardiotoxicity due to digoxin as well as by other glycosides.

Usage- in Europe as DIGIBIND (38 mg vial )


DIGIFAB(40mg/vial)given by i.v infusion
It is nonimmunogenic because it lacks Fc fragement
BIBLIOGRAPHY

FROM [Link] 8
TH

EDITION
ESSENTIAL OF MEDICAL
PHARMACOLOGY
THANKYOU..

You might also like